Corynoxine B: Opioid Activity, Addiction Relevance, and Safety Evidence

Executive Summary

Corynoxine B is a minor oxindole alkaloid found in kratom and several Uncaria species. Although studied mainly for autophagy and experimental neurodegenerative disease, newer research shows that it can activate the human mu-opioid receptor (MOR) in laboratory assays.

The strongest evidence comes from a 2026 study in which corynoxine B produced high-efficacy MOR-mediated cAMP signaling, with reported EC50 values of approximately 193–276 nM and maximal responses of about 81–90% [1]. No measurable beta-arrestin-2 recruitment was detected under those experimental conditions. Earlier studies reported much weaker or undetectable opioid activity, indicating that the precise potency and signaling profile remain assay-dependent [2,3].

These findings establish meaningful in-vitro MOR activity but do not demonstrate clinically significant opioid effects, addiction, or therapeutic benefit. Human data are lacking on dose, oral bioavailability, brain exposure, receptor occupancy, toxicity, tolerance, physical dependence, withdrawal, reinforcement, and treatment efficacy. Limited animal evidence indicates CNS activity under some conditions but does not resolve these questions.

Practical safety implication: Corynoxine B should not be considered pharmacologically inert, assumed safe because it shows little beta-arrestin recruitment, or promoted as an alternative opioid or addiction treatment. Until human pharmacokinetic and toxicological data are available, isolated or concentrated corynoxine B should be regarded as an investigational compound with an unresolved opioid-related safety profile.

What Is Corynoxine B?

Corynoxine B is an oxindole alkaloid reported in Mitragyna speciosa and several Uncaria species. It is structurally related to corynoxine, sometimes called corynoxine A in newer literature. The two molecules are stereoisomers: they share the same molecular formula but differ in three-dimensional configuration at a key spiro center.

That difference matters. Small stereochemical changes can substantially alter how a molecule fits into a receptor, how strongly it binds, and which intracellular signaling pathways it favors. In the kratom literature, corynoxine and corynoxine B should therefore not be treated as interchangeable compounds.

Corynoxine B occurs only as a minor constituent of kratom compared with mitragynine. That distinction is essential when extrapolating from purified-compound experiments to ordinary kratom leaf. A receptor assay using isolated corynoxine B does not show that corynoxine B is responsible for the dominant effects of traditional kratom preparations [3,7].

Why the Mu-Opioid Receptor Matters

The mu-opioid receptor is the principal target through which morphine, fentanyl, oxycodone, heroin metabolites, and many other opioid agonists produce analgesia and reward. Sustained MOR activation can also contribute to tolerance, physical dependence, withdrawal, respiratory depression, and reinforcement.

But receptor activity alone does not establish addiction.

Several concepts need to be separated:

• Affinity describes how strongly a compound binds to a receptor.
• Potency describes the concentration needed to produce a given effect.
• Efficacy describes how large a response the compound can produce in a particular assay.
• Signaling bias describes whether receptor activation preferentially engages one intracellular pathway over another.
• Pharmacokinetics determine whether enough drug reaches the receptor in a living organism.
• Reinforcement refers to whether a drug increases behaviors that obtain more of the drug.
• Physical dependence refers to physiological adaptation that can produce withdrawal when exposure stops.
• Addiction is a behavioral syndrome involving impaired control, compulsive use, and continued use despite harm.

Corynoxine B now has meaningful evidence in the first several categories. The later categories remain poorly studied.

The 2021 Studies Did Not Agree

One of the most important features of the corynoxine B literature is that different laboratories obtained very different opioid-receptor results.

Chakraborty et al. (2021)

A 2021 ACS Chemical Neuroscience study characterized several minor kratom alkaloids using opioid-receptor binding and functional assays. Corynoxine B showed weak binding in that experimental system, with reported affinity values greater than 1,000 nM, and no detectable activity in the study's [35S]GTPgammaS functional assay [2].

On the basis of that dataset alone, corynoxine B would have looked like a relatively unimportant opioid ligand.

Chear et al. (2021)

A separate investigation published the same year produced a strikingly different result. Chear and colleagues examined oxindole alkaloids from Malaysian Mitragyna speciosa and reported a human MOR Ki for corynoxine B of approximately 109.8 ± 8.1 nM [3].

In the same study, corynoxine showed considerably stronger affinity, around 16.4 nM. The difference reinforced the importance of distinguishing corynoxine B from its stereoisomer.

The discrepancy between the two 2021 papers is not a minor technical footnote. It demonstrates that corynoxine B's apparent opioid pharmacology is sensitive to assay design, receptor system, experimental conditions, or potentially other methodological factors.

The 2026 Study Changes the Picture

The strongest recent evidence comes from a 2026 study that examined kratom alkaloids across human mu-, kappa-, and delta-opioid receptors using multiple pharmacological approaches [1].

Corynoxine B behaved as a functional MOR agonist in cAMP experiments. Depending on the reported analysis, the study gave an EC50 in the approximate range of 193–276 nM, with maximal responses around 81–90% [1].

That matters because a binding assay only shows that a compound can occupy a receptor. A functional assay asks whether that binding actually changes receptor signaling. In this experimental system, corynoxine B did.

The result does not erase the earlier negative study. Instead, the combined literature suggests that corynoxine B's measured activity can vary substantially depending on the assay used. GTPgammaS activation and inhibition of forskolin-stimulated cAMP are both measures related to Gi/o-coupled receptor signaling, but they are not biologically identical endpoints.

A careful interpretation is therefore:

Multiple independent datasets now support interaction between corynoxine B and human MOR, and the strongest recent functional study demonstrates substantial MOR-mediated signaling in vitro. The exact potency and signaling profile remain assay-dependent and need independent replication.

G-Protein Bias and Beta-Arrestin-2

The 2026 study reported another notable finding: corynoxine B produced substantial MOR-mediated cAMP signaling without measurable beta-arrestin-2 recruitment under the experimental conditions used [1].

This pattern is often described as G-protein-biased agonism.

Historically, biased opioid signaling attracted intense interest because researchers hoped that G-protein-favoring agonists might preserve analgesia while reducing adverse effects associated with beta-arrestin pathways. The modern picture is much more complicated. Respiratory depression, tolerance, reinforcement, constipation, and other opioid effects cannot be cleanly divided into a simple "good G-protein / bad beta-arrestin" model.

Accordingly, lack of measurable beta-arrestin-2 recruitment should not be interpreted as evidence that corynoxine B is non-addictive, non-dependence-forming, or incapable of respiratory effects.

The most defensible statement is that corynoxine B displays an unusual signaling profile in current human-MOR assays, while the consequences of that profile in living organisms remain unknown.

Does Corynoxine B Cause Addiction?

There is currently no adequate evidence to answer that question in humans.

Two opposite overstatements should be avoided.

The first is: "Corynoxine B activates MOR, therefore it is addictive."

That conclusion goes beyond the evidence. MOR activation is a biologically meaningful hazard signal, but addiction requires behavioral and exposure data that receptor assays cannot provide.

The second is: "There are no addiction studies, therefore it is safe or non-addictive."

That conclusion is equally unsupported. The absence of a study does not establish the absence of a risk.

A rigorous abuse-liability program would normally include experiments such as drug self-administration, progressive-ratio responding, conditioned place preference, intracranial self-stimulation, drug discrimination, chronic tolerance testing, spontaneous withdrawal, antagonist-precipitated withdrawal, and reinstatement of drug seeking.

For corynoxine B itself, that evidence base is largely missing.

Physical Dependence May Be the More Immediate Question

Physical dependence is not the same thing as addiction.

A person can become physically dependent on a drug without developing compulsive drug-seeking behavior. Dependence reflects physiological adaptation: after repeated exposure, the nervous system adjusts to the drug's presence, and abrupt discontinuation can produce withdrawal.

Because corynoxine B can activate MOR in at least some modern assays, repeated exposure at sufficiently high systemic and brain concentrations could plausibly produce opioid-related neuroadaptation. That is a hypothesis grounded in mechanism, not a demonstrated clinical fact.

Critical unanswered questions include:

• Does repeated corynoxine B exposure produce tolerance?
• Does stopping it produce spontaneous withdrawal?
• Can naloxone precipitate withdrawal after chronic exposure?
• Does it produce cross-tolerance with other MOR agonists?
• What blood and brain concentrations would be required?
• Are those concentrations achievable through oral use?

Until those experiments exist, claims that corynoxine B either does or does not cause dependence remain premature.

Could Corynoxine B Treat Opioid Withdrawal?

There is no established clinical evidence that it can.

The hypothesis is understandable. A MOR-active compound can theoretically suppress withdrawal from another opioid by replacing some of the missing receptor stimulation. That principle contributes to the effectiveness of established medications such as methadone and buprenorphine.

But MOR activity by itself does not make a compound an appropriate treatment for opioid use disorder.

A medication intended for withdrawal or maintenance treatment needs predictable pharmacokinetics, reproducible composition, known dose-response relationships, toxicology, interaction data, controlled evidence of efficacy, and a favorable therapeutic index.

For isolated corynoxine B, these requirements have not been established.

There is currently no controlled human evidence demonstrating that corynoxine B safely treats opioid withdrawal, kratom dependence, 7-hydroxymitragynine dependence, opioid use disorder, stimulant use disorder, craving, or relapse.

It should therefore be described as a research question, not an evidence-based addiction therapy.

What About Stimulant Addiction?

Older animal work involving Uncaria alkaloids has reported CNS behavioral effects of corynoxine B under some experimental conditions, including suppression of drug-induced hyperlocomotion. Such findings can sound relevant to stimulant addiction, but they are easy to overinterpret.

Reduced hyperlocomotion is not the same thing as reduced reinforcement or compulsive drug taking. Sedation, motor impairment, dopamine-related effects, or broad CNS depression can all reduce movement without treating addiction.

No controlled evidence currently establishes corynoxine B as a treatment for methamphetamine or other stimulant-use disorders.

Autophagy Is the Better-Developed Corynoxine B Research Area

For most of its modern research history, corynoxine B was studied less as an opioid ligand and more as an autophagy-enhancing natural product.

Autophagy is a cellular recycling system through which cells degrade damaged proteins, organelles, and other material. Dysfunction in autophagy is implicated in several neurodegenerative disorders.

Corynoxine B has been studied particularly in relation to alpha-synuclein, a protein central to Parkinson's disease pathology. A 2023 study identified HMGB1 and HMGB2 as molecular targets involved in corynoxine-B-mediated autophagy and reported enhanced alpha-synuclein clearance across cellular, fly, and rodent models [4].

This creates an unusually broad pharmacological picture: corynoxine B has evidence for both intracellular autophagy-related effects and opioid-receptor signaling. Whether these mechanisms meaningfully interact in addiction biology is unknown.

Brain Penetration Is a Major Limitation

A crucial distinction in pharmacology is the difference between potency in a dish and potency in a person.

For a centrally acting MOR ligand, the relevant chain is not simply receptor EC50. It is:

dose -> absorption -> plasma exposure -> protein binding -> metabolism -> blood-brain barrier penetration -> unbound brain concentration -> receptor occupancy -> physiological effect.

Research on corynoxine B suggests that the parent compound has limited brain permeability. This limitation was significant enough that investigators developed derivatives specifically to improve CNS exposure.

One derivative, CB6, was designed to improve brain penetration while preserving autophagy-related activity. In preclinical Parkinsonian models, CB6 induced PIK3C3-complex-dependent autophagy and produced neuroprotective effects [5].

A separate 2023 study used Fe65-engineered neuronal exosomes to deliver corynoxine B to the brain in an Alzheimer's disease mouse model. The delivery system increased brain exposure and was associated with improved pathological and behavioral outcomes under those experimental conditions [6].

These studies reinforce an important point for addiction risk: strong receptor activity in vitro does not tell us how much unmodified corynoxine B reaches human brain MOR after oral exposure.

Corynoxine B Is Not 7-Hydroxymitragynine

Corynoxine B should not be confused with 7-hydroxymitragynine (7-HMG).

Both occur within the broader chemistry of kratom, but they are distinct compounds with different structures, potency, abundance, metabolism, and evidence bases.

In the 2026 human-MOR cAMP experiments, 7-HMG showed much greater potency than corynoxine B, with low-nanomolar activity compared with corynoxine B's low-hundreds-of-nanomolar range [1].

That comparison does not mean that one can convert the receptor-potency ratio into a human dose ratio. Different compounds can have very different oral absorption, metabolism, brain penetration, protein binding, elimination, and active metabolites.

Receptor potency is not dose potency.

Corynoxine B Is Also Not Corynoxine

The distinction between corynoxine and corynoxine B may be even more important.

Chear and colleagues reported substantially stronger MOR affinity for corynoxine than for corynoxine B [3]. Other preclinical opioid experiments have also been conducted with corynoxine itself.

Those findings should not automatically be transferred to corynoxine B simply because the names are similar.

When reading commercial claims or secondary literature, it is worth checking whether the cited study actually tested corynoxine B, corynoxine, or a mixture containing both.

Human Evidence Is the Major Missing Piece

For isolated corynoxine B, the clinically important evidence gaps remain large.

No adequate human evidence currently establishes:

• a therapeutic dose;
• a psychoactive dose;
• oral bioavailability;
• elimination half-life;
• brain concentrations after oral use;
• MOR occupancy;
• an acute toxicity threshold;
• chronic toxicity;
• respiratory-depression risk;
• tolerance liability;
• physical-dependence liability;
• a characteristic withdrawal syndrome;
• reinforcing or rewarding effects;
• abuse potential;
• or efficacy for any substance-use disorder.

That level of uncertainty should fundamentally change how purified or concentrated corynoxine B is discussed.

The absence of documented human harm cannot be treated as evidence of safety when human exposure itself has barely been characterized.

Safety and Drug-Interaction Uncertainty

There is not enough evidence to define a safe isolated human dose of corynoxine B.

Important unresolved areas include respiratory effects at high exposure, cardiovascular effects, repeated-dose liver and kidney toxicity, CYP-mediated interactions, effects when combined with alcohol, interactions with benzodiazepines or other sedatives, interactions with opioids, and interactions with other kratom alkaloids.

These unknowns matter especially for concentrated preparations. Natural abundance in a plant does not establish the safety of a purified or enriched ingredient. Concentration changes exposure, and exposure is a central determinant of pharmacological risk.

Evidence Map

What Research Is Needed Next?

The unanswered questions are experimentally tractable.

Independent replication of MOR pharmacology

Multiple laboratories should test chemically verified corynoxine B using matched material across radioligand binding, GTPgammaS activation, cAMP inhibition, mini-G-protein recruitment, beta-arrestin recruitment, receptor internalization, and electrophysiological assays.

This would help explain why the existing studies diverge so sharply.

Pharmacokinetics

Studies need to establish oral bioavailability, half-life, metabolites, plasma protein binding, brain-to-plasma ratios, unbound brain concentrations, and dose-exposure relationships.

Abuse-liability testing

Drug self-administration, progressive-ratio testing, conditioned place preference, intracranial self-stimulation, drug discrimination, and reinstatement experiments would help determine whether corynoxine B has reinforcing properties.

Chronic dependence testing

Repeated administration followed by spontaneous withdrawal and antagonist-precipitated withdrawal would directly test physical dependence.

Respiratory and toxicological studies

Researchers should characterize respiratory effects, cardiovascular safety, organ toxicity, genotoxicity, and major drug-interaction pathways before meaningful human safety claims are made.

Conclusion

Current evidence supports substantial MOR-mediated signaling by corynoxine B in vitro, including high efficacy and little detectable beta-arrestin-2 recruitment in the strongest recent study [1]. Earlier studies found weaker or absent activity, however, and the compound's potency, signaling profile, pharmacokinetics, and real-world effects remain uncertain [2,3].

MOR activity is a legitimate safety signal, not proof of addiction. It remains unknown whether corynoxine B produces clinically meaningful opioid effects, reinforcement, tolerance, physical dependence, withdrawal, respiratory depression, or addiction in humans. Its absorption, metabolism, brain penetration, receptor occupancy, and exposure-response relationships are also inadequately characterized.

Corynoxine B should therefore be viewed as an understudied, pharmacologically active compound with plausible opioid-related risks—not a proven addictive opioid, but not a demonstrated safe alternative. It should not be used or marketed to treat opioid withdrawal, substance-use disorder, or other conditions without controlled pharmacokinetic, toxicological, behavioral, and clinical evidence.

The most important scientific question is no longer simply whether corynoxine B can interact with opioid receptors. Current evidence indicates that it can. The important unanswered questions are how much reaches the human brain, what receptor occupancy occurs at real-world exposures, whether repeated exposure produces dependence or reinforcement, and whether its unusual signaling profile meaningfully changes opioid-related risk.

Until those questions are answered, uncertainty itself is part of the evidence.